Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Radiology

Biology, Symptoms, and the Diagnostic Pathway

At a Glance

Alveolar echinococcosis is a slow-growing parasitic liver infection that can resemble liver cancer. Diagnosis combines exposure history, ultrasound, CT, MRI, selected PET/CT, antibody tests, and carefully planned biopsy when needed.

Understanding alveolar echinococcosis (AE) requires looking at it through two lenses: its biology as a parasite and its behavior as a tumor-like invader. Because AE grows slowly and silently, the diagnostic pathway is often complex, involving multiple types of imaging and blood tests to distinguish it from liver cancer.

The Biological Journey

The parasite responsible for AE, Echinococcus multilocularis, follows a specific life cycle that involves animals. Humans enter this cycle by accident, becoming aberrant hosts—meaning the parasite has reached a “dead end” in us and cannot complete its natural life cycle [1][2].

  • Definitive Hosts: Animals like foxes, coyotes, and dogs carry the adult tapeworm in their intestines. They shed microscopic eggs in their feces [1].
  • Intermediate Hosts: In nature, small rodents (like voles or mice) eat the eggs. The parasite then develops into a larval stage in the rodent’s liver [2].
  • Human Infection: You can only become infected by accidentally ingesting these microscopic eggs. This typically happens through hand-to-mouth transfer after touching contaminated soil, unwashed produce (like wild berries or mushrooms), or the fur of an infected dog or fox [3][4]. Touching fur alone does not cause infection; the eggs must be swallowed.

Once inside a human, the parasite behaves differently than it does in a rodent. Instead of staying contained, it begins a slow, “infiltrative” growth in the liver, mimicking the way a malignant tumor spreads into surrounding tissues [5].

Distinguishing AE from Liver Cancer

One of the greatest challenges in diagnosing AE is that it can look remarkably like several types of liver cancer. Doctors must carefully differentiate AE from its “look-alikes”:

  • Hepatocellular Carcinoma (HCC): The most common primary liver cancer.
  • Intrahepatic Cholangiocarcinoma (ICC): Cancer of the bile ducts inside the liver.
  • Liver Metastases: Cancer that has spread to the liver from another organ (like the colon or lungs).

To tell them apart, radiologists look for specific clues. While imaging appearances overlap and cancers can also be necrotic, AE lesions often lack a central blood supply because the center of the parasite mass is often dead or necrotic (tissue death) [6][7]. Because no single imaging feature is a perfect rule, diagnosis requires expert integration of imaging, blood tests, and clinical history.

The Diagnostic Imaging Pathway

No single scan can provide the whole picture. Instead, doctors use a “staircase” of imaging to build a complete diagnosis.

1. Ultrasound: The First Look

Ultrasound is often the first test used. It can reveal classic patterns that strongly suggest AE [8]:

  • “Hailstorm” Pattern: A patchy, heterogeneous appearance that looks like a storm on the screen. This is the most common pattern [9].
  • “Pseudocystic” Pattern: A large, fluid-filled area that can be mistaken for a simple liver cyst but has irregular walls and internal debris [8].

2. CT and MRI: Mapping the Damage

Once a lesion is found, Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) are used to see exactly where the parasite is.

  • CT Scans: Excellent for finding calcifications (hard, chalky deposits). Many AE lesions show some form of calcification, which is a key sign that helps distinguish it from most cancers [10][11].
  • MRI: Superior for seeing how the parasite is affecting the “plumbing” of the liver—the bile ducts and major blood vessels [12].

3. PET/CT: Checking for Inflammation

A Positron Emission Tomography (PET) scan is used selectively as an adjunct to see metabolic activity. The scan measures a value called SUVmax, which reflects host inflammation around the parasite [13][14]. A PET scan shows where the body is actively fighting it. It is important to know that low uptake does not guarantee all viable parasite is gone, so PET is always combined with MRI/CT and specialist judgment.

The Role of Serology and Biopsy

Blood tests, known as serology, look for specific antibodies (like Em-18 or Em2) that your immune system creates to fight the parasite [15]. These tests are very helpful but aren’t always 100% accurate, especially in the very early or very late stages of the disease [16].

Biopsy (taking a small tissue sample) is carefully considered by the expert team when malignancy cannot be excluded. If a biopsy is necessary, it must be planned carefully by specialists to evaluate risks. Sampling the center of the lesion often yields only “dead tissue,” which can lead to a false-negative result, while sampling the “active rim” requires expertise [17][7]. Do not arrange for a biopsy outside of your multidisciplinary AE care team’s plan.

Completeness Checklist: What Your Reports Should Include

When reviewing your imaging or pathology reports with your doctor, ensure they address these specific details:

Category What to Look For Why It Matters
Morphology Classification (e.g., EMUC/AEUC type) [10] Helps predict how the disease will behave.
Calcification Pattern and location (central vs. peripheral) [18] Strongly supports an AE diagnosis over cancer.
Vascular Involvement Contact with the portal vein, hepatic veins, or vena cava [19] Determines if surgery is a safe option.
Biliary Involvement Dilation or blockage of bile ducts [5] Explains symptoms like jaundice or itching.
PET Activity SUVmax (reflecting host inflammation) [20] Indicates the immune system’s response.
Pathology (if done) Presence of a “laminated layer” or PAS-positive membranes [21] The “gold standard” proof of the parasite.
Staging PNM Stage (P=Liver, N=Nearby organs, M=Metastasis) [22] Summarizes the overall anatomical extent.

Common questions in this guide

How is alveolar echinococcosis transmitted to people?
People become infected only when they swallow microscopic eggs of Echinococcus multilocularis. Eggs may be transferred from contaminated soil, unwashed wild produce, or an infected dog or fox to the mouth; simply touching animal fur does not cause infection unless eggs are ingested.
What symptoms can alveolar echinococcosis cause?
Alveolar echinococcosis may grow silently for a long time, so some people have few early symptoms. As the liver or bile ducts become involved, possible symptoms include dull abdominal pain, jaundice, itching, and significant weight loss.
How can doctors distinguish alveolar echinococcosis from liver cancer?
Alveolar echinococcosis can resemble hepatocellular carcinoma, bile-duct cancer, or cancer that has spread to the liver. Doctors combine imaging clues such as calcification, dead tissue, and the pattern of involvement with blood tests and exposure history; no single scan finding is conclusive.
Which scans are used to diagnose alveolar echinococcosis?
Ultrasound is often the first test and may show a hailstorm or pseudocystic pattern. CT helps identify calcifications, MRI maps the bile ducts and blood vessels, and PET/CT may be added to assess inflammation; these results are interpreted together.
What do Em-18 and Em2 antibody tests tell you?
Em-18 and Em2 blood tests detect antibodies made in response to the parasite and can support an alveolar echinococcosis diagnosis. The results are not perfect, particularly in very early or very late disease, so doctors interpret them with imaging and clinical history.
When is a biopsy needed for suspected alveolar echinococcosis?
A biopsy may be considered when cancer cannot be ruled out, but it should be planned by an expert alveolar echinococcosis team rather than arranged independently. Sampling the dead center of a lesion may produce a false-negative result, while sampling the active rim requires specialist expertise.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Do my ultrasound patterns resemble the 'hailstorm' or 'pseudocystic' types common in AE?
  2. 2.How does my imaging distinguish this lesion from look-alike conditions like liver cancer (HCC) or cholangiocarcinoma?
  3. 3.Is my serology (Em-18 or Em2 antibodies) positive, and how does that help confirm the diagnosis?
  4. 4.Does the PET/CT show active metabolic inflammation around the edges of the lesion, and how will we use this for future monitoring?
  5. 5.If you are considering a biopsy, what steps will you take to ensure you sample the active rim rather than the necrotic center?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Global Distribution of Alveolar and Cystic Echinococcosis.

    Deplazes P, Rinaldi L, Alvarez Rojas CA, et al.

    Advances in parasitology 2017; (95()):315-493 doi:10.1016/bs.apar.2016.11.001.

    PMID: 28131365
  2. 2

    A systematic review and meta-analysis on anthelmintic control programs for Echinococcus multilocularis in wild and domestic carnivores.

    Umhang G, Possenti A, Colamesta V, et al.

    Food and waterborne parasitology 2019; (15()):e00042 doi:10.1016/j.fawpar.2019.e00042.

    PMID: 32095614
  3. 3

    Intense Focus of Alveolar Echinococcosis, South Kyrgyzstan.

    Bebezov B, Mamashev N, Umetaliev T, et al.

    Emerging infectious diseases 2018; (24(6)):1119-1122 doi:10.3201/eid2406.161641.

    PMID: 29774832
  4. 4

    First detection of Echinococcus multilocularis in environmental water sources in endemic areas using capsule filtration and molecular detection methods.

    Lass A, Szostakowska B, Kontogeorgos I, et al.

    Water research 2019; (160()):466-474 doi:10.1016/j.watres.2019.05.050.

    PMID: 31174074
  5. 5

    Disseminated alveolar echinococcosis resembling metastatic malignancy: a case report.

    Caire Nail L, Rodríguez Reimundes E, Weibel Galluzzo C, et al.

    Journal of medical case reports 2017; (11(1)):113 doi:10.1186/s13256-017-1279-2.

    PMID: 28416007
  6. 6

    Contrast-enhanced ultrasound (CEUS) in patients with metastasis-like hepatic alveolar echinococcosis: a cohort study.

    Schweizer M, Schmidberger J, Schlingeloff P, Kratzer W

    Journal of ultrasound 2023; (26(1)):129-136 doi:10.1007/s40477-022-00688-x.

    PMID: 35597873
  7. 7

    Hepatic alveolar echinococcosis mimicking cholangiocarcinoma: a case study.

    Wang Y, Dong T, Yang D, et al.

    BMC infectious diseases 2026; (26(1)).

    PMID: 41882584
  8. 8

    Proposal of an ultrasonographic classification for hepatic alveolar echinococcosis: Echinococcosis multilocularis Ulm classification-ultrasound.

    Kratzer W, Gruener B, Kaltenbach TE, et al.

    World journal of gastroenterology 2015; (21(43)):12392-402 doi:10.3748/wjg.v21.i43.12392.

    PMID: 26604646
  9. 9

    Ultrasound images in hepatic alveolar echinococcosis and clinical stage of the disease.

    Sulima M, Nahorski W, Gorycki T, et al.

    Advances in medical sciences 2019; (64(2)):324-330 doi:10.1016/j.advms.2019.04.002.

    PMID: 31003201
  10. 10

    Proposal of a computed tomography classification for hepatic alveolar echinococcosis.

    Graeter T, Kratzer W, Oeztuerk S, et al.

    World journal of gastroenterology 2016; (22(13)):3621-31 doi:10.3748/wjg.v22.i13.3621.

    PMID: 27053854
  11. 11

    Hepatic Alveolar Echinococcosis Mimicking Perihilar Cholangiocarcinoma: A Case Report.

    Karam K, Charro K, Morini A, et al.

    Clinical medicine insights. Case reports 2026; (19()):11795476261470690 doi:10.1177/11795476261470690.

    PMID: 42466095
  12. 12

    Intrahepatic manifestation and distant extrahepatic disease in alveolar echinococcosis: a multicenter cohort study.

    Graeter T, Shi R, Bao H, et al.

    Acta radiologica (Stockholm, Sweden : 1987) 2021; (62(8)):997-1005 doi:10.1177/0284185120951958.

    PMID: 32847367
  13. 13

    Hepatic alveolar echinococcosis: correlation between computed tomography morphology and inflammatory activity in positron emission tomography.

    Graeter T, Eberhardt N, Shi R, et al.

    Scientific reports 2020; (10(1)):11808 doi:10.1038/s41598-020-68624-9.

    PMID: 32678174
  14. 14

    Sectional Imaging for Alveolar Echinococcosis.

    Eberhardt N, Haggenmüller B

    Visceral medicine 2025; (41(6)):320-327 doi:10.1159/000548686.

    PMID: 41376838
  15. 15

    Pitfalls in diagnosis and treatment of alveolar echinococcosis: a sentinel case series.

    Stojkovic M, Mickan C, Weber TF, Junghanss T

    BMJ open gastroenterology 2015; (2(1)):e000036 doi:10.1136/bmjgast-2015-000036.

    PMID: 26462284
  16. 16

    18FDG-PET/CT-Scans and Biomarker Levels Predicting Clinical Outcome in Patients with Alveolar Echinococcosis-A Single-Center Cohort Study with 179 Patients.

    Peters L, Jiang W, Eberhardt N, et al.

    Pathogens (Basel, Switzerland) 2023; (12(8)) doi:10.3390/pathogens12081041.

    PMID: 37624001
  17. 17

    The initial stage of alveolar echinococcosis is a diagnostic challenge: a case report.

    Graeter T, Schmidberger J, Shi R, et al.

    Journal of medical case reports 2025; (19(1)):349 doi:10.1186/s13256-025-05298-9.

    PMID: 40671141
  18. 18

    Virtual non-enhanced dual-energy computed tomography reconstruction: a candidate to replace true non-enhanced computed tomography scans in the setting of suspected liver alveolar echinococcosis.

    Kantarcı M, Aydın S, Kahraman A, et al.

    Diagnostic and interventional radiology (Ankara, Turkey) 2023; (29(6)):736-740 doi:10.4274/dir.2023.221806.

    PMID: 37042415
  19. 19

    Vascular pathology in patients with alveolar echinococcosis: framework for assessment and clinical management - a retrospective case series.

    Gieser P, Merle U, Junghanss T, et al.

    BMJ open gastroenterology 2023; (10(1)) doi:10.1136/bmjgast-2023-001181.

    PMID: 37567730
  20. 20

    Diagnosis of hepatic alveolar echinococcosis:18F-FDG-PET activity compared to the Echinococcus multilocularis Ulm Ultrasound Classification.

    Kratzer W, Steinkellner S, Skotnik D, et al.

    Nuklearmedizin. Nuclear medicine 2026; (65(1)):4-12 doi:10.1055/a-2744-4139.

    PMID: 41326002
  21. 21

    Macroscopic and Microscopic Aspects of Echinococcus multilocularis and Echinococcus granulosus in Humans: A Guideline for Pathologists.

    Frey H, Barth TFE

    Visceral medicine 2025; doi:10.1159/000548706.

    PMID: 41394247
  22. 22

    Programmed death-ligand1 is a determinant of recurrence in alveolar echinococcosis.

    Joliat GR, Martins-Filho SN, Haefliger S, et al.

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2023; (129()):285-288 doi:10.1016/j.ijid.2023.01.043.

    PMID: 36775187

This page is for informational purposes only and does not constitute medical advice. A multidisciplinary team experienced with alveolar echinococcosis should interpret your imaging, blood tests, and biopsy decisions.

Get notified when new evidence is published on Alveolar echinococcosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.